Objective To investigate the serum Decoy Receptor 3 (DcR3) level in patients with chronic obstructive pulmonary disease (COPD) and to investigate the correlation of DcR3 with airflow restriction, quality of life and acute exacerbations within 1 year. Methods From August 2021 to August 2022, 81 patients with moderate to severe COPD were included as study subjects. Serum DcR3 levels were measured by enzyme-linked immunosorbent assay, and the correlation of serum DcR3 with airflow restriction and quality of life was analyzed by Spearman correlation analysis. The clinical factors influencing acute exacerbations within 1 year were analyzed by binary Logistic regression, and the clinical value of serum DcR3 in predicting acute exacerbations within 1 year was analyzed by receiver operating characteristic (ROC) curve. Results Compared with the serum DcR3≥2.45 ng/ml (median) group, the basophil count in the serum DcR3<2.45 ng/ml group significantly increased (P<0.05), and the number of acute exacerbation and hospitalizations within 1 year significantly decreased (P<0.05). Serum DcR3 was negatively correlated with forced expiratory volume in the first second (FEV1) (r=-0.389), FEV1/forced vital capacity (FVC) (r=-0.610), diffusing capacity of the lungs for carbon monoxide (r=-0.611), and inspiratory volume (IC)/total lung ratio (TLC) (r=-0.862), all P<0.05. There was a positive correlation between serum DcR3 and COPD assessment test (CAT) (r=0.638), visual analogue scale (VAS)-cough (r=0.282), VAS-sputum (r=0.269) and VAS-purulent sputum (r=0.237) scores, all P<0.05. Interleukin (IL)-6 was negatively correlated with 75% of the maximum expiratory flow rate (r=-0.481), and C-reactive protein (CRP) was positively correlated with CAT score (r=0.521), both P<0.05. By binary logistic regression, serum DcR3 was independently correlated with acute exacerbations of COPD within one year (P<0.05).The area under the curve of serum DcR3 in predicting acute exacerbations in COPD patients within 1 year was [0.788 (95%CI: 0.688～0.888)], and the sensitivity (0.689) and specificity (0.833) were the highest when serum DcR3≥2.435 ng/ml. Conclusions Serum DcR3 is associated with airflow restriction, quality of life, disease severity and acute onset within 1 year in COPD patients, and serum DcR3 level has potential as a marker of pathogenesis of COPD patients.
Key words
chronic obstructive pulmonary disease /
decoy receptor 3 /
airflow restriction /
quality of life /
acute exacerbation
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Aslani M R, Ghazaei Z, Ghobadi H. Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD[J]. Turk J Med Sci, 2020, 50(2): 337-345.
[2] Owusuaa C, Leest C, Helfrich G, et al. The development of the ADO-SQ model to predict 1-year mortality in patients with COPD[J]. Palliat Med, 2022, 36(5): 821-829.
[3] 刘 雯, 费维伦, 梁春阳, 等. 血清DcR3对COPD急性加重期患者预后评估的应用价值[J]. 中国急救复苏与灾害医学杂志,2022,17(2):225-229.
[4] Kamal A, Abdelmegeid A K, Gabr M A, et al. Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children[J]. Immunol Res, 2021, 69(6): 568-575.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021,44(3) : 170-205.
[6] 夏君燕, 张 英, 高永红. 老年COPD急性加重期患者血清miR-448-5p、Six1水平及其临床意义[J]. 国际检验医学杂志,2023,44(14):1737-1742.
[7] 黄长明, 吴 瑕, 张 冉, 等. COPD急性加重期患者血清SIRT1与炎症因子水平的相关性及临床意义[J]. 中南医学科学杂志,2023,51(6):931-933.
[8] Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine[J]. Eur Respir J, 2019, 54(2): 1900651-1900663.
[9] Xue Q, Xie Y, He Y, et al. Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study[J]. Sci Rep, 2023, 13(1): 5715-5725.
[10] 陈 灿, 郑林鑫, 麦玉梅, 等. 慢性阻塞性肺疾病并骨质疏松患者血清IL-6、TNF-α水平的变化及其对OPG、RANKL表达的影响[J]. 临床肺科杂志,2023,28(1):35-38.
[11] 胡斯育, 杨浩军, 杨 凡,等. 维生素D对COPD稳定期患者血清TNF-α、IL-6及肺功能的影响[J]. 湖南师范大学学报(医学版),2019,16(3):38-40.
[12] Su J, Tong Z, Wu S, et al. Research Progress of DcR3 in the diagnosis and treatment of sepsis[J]. Int J Mol Sci, 2023, 24(16): 12916-12930.
[13] 谷丽华, 贺晶晶, 袁佳健, 等. DCR3、CRP/Alb、Trx与细菌性肝脓肿并发感染性休克的相关性[J]. 肝脏,2023,28(10):1227-1230,1256.
[14] 龚 峰, 张 莉, 周 莉. 血清endocan、DcR3与支气管哮喘患儿气道炎症的关系[J]. 国际检验医学杂志,2024,45(2):165-169.
[15] 侯丽娟, 王文文, 翟建军, 等. 血清HIF-1α、DcR3、TSGF在宫颈癌诊断中的作用及其与患者临床病理参数的关系[J]. 山东医药,2021,61(11):52-55.
[16] 邢燕平, 任红娟, 王 欣. 诱骗受体3(DcR3)与人上皮卵巢癌患者预后的关系[J]. 实用癌症杂志,2022,37(5):736-738.
[17] 赵佳媛, 许婷婷, 吴 笛, 等. DcR3 ALB水平与慢阻肺急性加重期合并呼衰患者转归关系[J]. 河北医学,2021,27(9):1436-1440.
[18] 刘 敏,王立芹, 杨茂勇, 等. 血清肿瘤坏死因子受体-6水平对AECOPD合并呼吸衰竭患者转归的影响.中国医师杂志,2019,21(8):1181.
[19] Ghobadi H, Hosseini N, Aslani M R. Correlations between serum decoy receptor 3 and airflow limitation and quality of life in male patients with stable stage and acute exacerbation of COPD[J]. Lung, 2020, 198(3): 515-523.
PDF(1365 KB)
